空間基因組學和轉錄組學市場:按產品類型、樣本類型、工作流程、應用、最終用戶和地區進行的全球分析和預測(2024-2034 年)
市場調查報告書
商品編碼
1667210

空間基因組學和轉錄組學市場:按產品類型、樣本類型、工作流程、應用、最終用戶和地區進行的全球分析和預測(2024-2034 年)

Spatial Genomics and Transcriptomics Market - A Global and Regional Analysis: Focus on Product Type, Sample Type, Workflow, Application, End User, and Region - Analysis and Forecast, 2024-2034

出版日期: | 出版商: BIS Research | 英文 115 Pages | 商品交期: 1-5個工作天內

價格

全球空間基因組學和轉錄組學市場規模預計將從 2023 年的 5.739 億美元激增至 2034 年的 21.586 億美元,預測期內的複合年成長率為 12.54%。

市場正在經歷顯著的成長,主要是由於空間體學在藥物發現和行銷中的應用越來越廣泛、定序技術的進步、對高解析度單細胞分析的需求不斷成長以及癌症和神經系統疾病等複雜疾病的患病率不斷上升。此外,隨著研究人員和臨床醫生尋求在分子水平上更準確地了解疾病機制,空間基因組學在個人化醫療和精準腫瘤學中的日益廣泛的應用預計將推動市場的發展。

主要市場統計數據
預測期 2024-2034
2024 年評估 6.623億美元
2034 年預測 21.586億美元
複合年成長率 12.54%

由於政府和私人機構對基因組學研究的投資不斷增加,以及生物技術公司和學術機構之間的合作,全球太空基因組學和轉錄組學市場正在經歷顯著成長,從而加速了空間分析技術的採用。隨著對空間轉錄組學的投資不斷增加,該領域將實現顯著的成長和突破。持續的資金支持無疑將促進空間基因表現分析的進一步發展,增強其重塑研究範式和重新定義精準醫療邊界的潛力。

按產品類型分類,套件和檢測試劑佔據主導地位:

根據產品類型,套件和檢測部分預計將在 2023 年佔據最大佔有率,預計到 2034 年將達到 11.162 億美元,預測期內的複合年成長率為 12.27%。這項優勢源自於它們在空間分析工作流程中的重要作用,為樣本製備、染色和檢測提供關鍵試劑和工具。這些產品的應用包括單細胞分析、組織分析和藥物發現,在腫瘤學、免疫學、神經科學和其他研究領域至關重要。此外,隨著許多研究機構和製藥公司擴大轉向外包服務以進行客製化分析、資料解釋和生物標記發現,服務業也正在獲得發展動力。如此強大的產品加上不斷擴展的服務能力預計將在未來幾年推動整個空間基因組學和轉錄組學市場的成長。

根據樣本類型,新鮮冷凍組織部分占主導地位:

根據樣本類型,新鮮冷凍組織部分預計將在 2023 年佔據最大佔有率,預計到 2034 年將達到 11.318 億美元,預測期內的複合年成長率為 12.40%。新鮮冷凍組織是採集後立即冷凍的生物組織,以保持其分子完整性。此領域的成長主要源自於臨床研究和診斷應用對保存組織完整形態、蛋白質、DNA 和 RNA 的需求。新鮮冷凍組織保持其結構完整性並提供研究實驗所必需的最佳通透條件。

根據工作流程,空間成像部分占主導地位:

根據工作流程,空間成像部分預計將在 2023 年佔據最大佔有率,預計到 2034 年將達到 10.957 億美元,預測期內的複合年成長率為 12.29%。空間成像可以探勘遺傳物質(DNA)和基因[去除]RNA)在其原生組織環境中的空間組織。受成像技術、質譜流式細胞儀和質譜技術創新的推動,這一領域正在經歷顯著的成長。此外,人工智慧和機器學習(ML)的進步進一步提高了影像重建的準確性和效率,使得即時空間成像越來越逼真。透過利用大型資料集和自適應學習演算法,AI 和 ML 解決了現有的限制,並以更高的準確性和速度增強了影像處理和解釋。

細分一:依產品類型

  • 套件和檢測試劑
    • 樣品製備套件
    • 樣品濃縮套件
  • 裝置
    • 幻燈片掃描儀
    • 顯微鏡
    • 質譜流式細胞儀
  • 軟體
  • 服務

細分 2:依樣本類型

  • 新鮮冷凍組織
  • 固定冷凍組織
  • 福馬林固定石蠟包埋 (FFPE) 組織
  • 培養細胞

細分 3:依工作流程

  • 空間成像
    • 雷射捕獲晶粒(LCM)
    • 免疫組織化學 (IHC)
    • 螢光原位雜合技術(FISH)
    • 顯微鏡
    • 條碼
    • 其他
  • 空間定序
    • 次世代定序(NGS)
    • 體內轉錄
    • 螢光原位定序(FISSEQ)
    • 切片定序
    • 其他
  • 空間分析
    • 資料視覺化工具
    • 資料分析工具

細分 4:按應用

  • 診斷
    • 癌症診斷
    • 神經系統疾病診斷
    • 免疫疾病診斷
    • 其他
  • 轉化研究
  • 藥物研發
  • 單細胞分析
  • 細胞生物學
  • 其他

細分 5:按最終用戶

  • 學術及研究機構
  • 生物製藥和生物技術公司
  • 受託研究機構
  • 其他

地理細分

  • 北美洲
    • 美國
    • 加拿大
  • 歐洲
    • 德國
    • 英國
    • 法國
    • 義大利
    • 西班牙
    • 其他
  • 亞太地區
    • 中國
    • 日本
    • 印度
    • 澳洲
    • 新加坡
    • 其他
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 其他
  • 中東和非洲

本報告研究了全球空間基因組學和轉錄組學市場,並總結了主要趨勢,分析了市場影響因素、法律制度、市場規模趨勢和預測,並按各個細分市場、地區/主要國家進行了詳細分析,介紹了競爭格局,並介紹了主要企業的概況。

目錄

執行摘要

範圍和定義

1. 全球空間基因體學與轉錄組學市場概覽

  • 市場概況
  • 法律規範
    • 美國
    • EU
    • 日本
    • 中國
  • 專利分析
    • 專利申請趨勢(按國家)
    • 專利申請趨勢(按年份)
    • 供應鏈分析
    • 價值鏈分析
  • 市場動態概覽
    • 市場促進因素
    • 市場限制
    • 市場機會

2. 全球空間基因體學和轉錄組學市場(按產品分類)

  • 套件和檢測試劑
    • 樣品製備套件
    • 樣本濃縮試劑套件
  • 裝置
    • 幻燈片掃描儀
    • 顯微鏡
    • 質譜流式細胞儀
  • 軟體
  • 服務

3. 全球空間基因體學和轉錄組學市場(按樣本類型)

  • 新鮮冷凍組織
  • 固定冷凍組織
  • 福馬林固定石蠟包埋 (FFPE) 組織
  • 培養細胞

4. 全球空間基因體學和轉錄組學市場(按工作流程)

  • 空間成像
    • 雷射捕獲晶粒(LCM)
    • 免疫組織化學 (IHC)
    • 螢光原位雜合技術(FISH) 培養細胞
    • 顯微鏡
    • 條碼
    • 其他
  • 空間定序
    • 次世代定序(NGS)
    • 體內轉錄
    • 螢光定序(FISSEQ)
    • 切片定序
    • 其他
  • 空間分析
    • 資料視覺化工具
    • 資料分析工具

5. 全球空間基因體學和轉錄組學市場(按應用)

  • 診斷
    • 癌症診斷
    • 神經學診斷
    • 免疫診斷
    • 其他診斷
  • 藥物研發
  • 轉化研究
  • 單細胞分析
  • 細胞生物學
  • 其他

6. 全球空間基因體學和轉錄組學市場(按最終用戶分類)

  • 學術及研究機構
  • 生物製藥和生物技術公司
  • CRO
  • 其他

7. 全球空間基因體學和轉錄組學市場(按地區)

  • 北美洲
  • 歐洲
  • 亞太地區
  • 拉丁美洲
  • 中東和非洲
    • 區域概況
    • 市場成長動力
    • 市場問題

第8章競爭考察與公司簡介

  • 關鍵策略和發展
  • 公司簡介
    • 10x Genomics.
    • Akoya Biosciences, Inc.
    • Bruker Corporation
    • Bio-Techne.
    • BioSpyder, Inc.
    • Flagship Biosciences, Inc.
    • Illumina, Inc.
    • Miltenyi Biotec
    • MGI Tech Co., Ltd.
    • RareCyte, Inc.
    • Revvity, Inc.
    • S2 Genomics, Inc.
    • Standard BioTools
    • TissueGnostics GmbH
    • Vizgen Inc.

第9章調查方法

Product Code: BHP1009SB

Introduction of Spatial Genomics and Transcriptomics

The global spatial genomics and transcriptomics market, initially valued at $573.9 million in 2023, is set to witness substantial growth, projected to surge to $2,158.6 million by 2034, marking a remarkable compound annual growth rate (CAGR) of 12.54% over the period from 2024 to 2034. The market has been experiencing significant growth, primarily fuelled by the increasing use of spatial omics for drug discovery and development, advancements in sequencing technologies, increasing demand for high-resolution single-cell analysis, and the rising prevalence of complex diseases such as cancer and neurological disorders. Moreover, the increasing applications of spatial genomics in personalized medicine and precision oncology are expected to expand the market as researchers and clinicians seek more accurate insights into disease mechanisms at the molecular level.

Market Introduction

KEY MARKET STATISTICS
Forecast Period2024 - 2034
2024 Evaluation$662.3 Million
2034 Forecast$2,158.6 Million
CAGR12.54%

The global spatial genomics and transcriptomics market has been experiencing significant growth, fueled by growing investments in genomics research by government and private organizations and collaborations between biotech firms and academic institutions, and is accelerating the adoption of spatial analysis techniques. As investment in spatial transcriptomics continues to rise, the field is positioned for significant growth and transformative breakthroughs. The ongoing financial support will undoubtedly catalyze further advancements in spatial gene expression analysis, reinforcing its potential to reshape research paradigms and redefine the boundaries of precision medicine. For instance, in 2024, Moleculent AB secured $26 million in a Series A financing round led by ARCH Venture Partners and co-led by Eir Ventures. The company's innovative functional biology platform enables the detection and profiling of cell interactions directly within their native tissue environments. Therefore, such financial support supports technological innovations and expands spatial transcriptomics applications in various research domains.

Industrial Impact

The spatial genomics and transcriptomics market has significantly influenced the healthcare landscape, driven by key players such as 10x Genomics, Illumina, Inc., and Akoya Biosciences, Inc. These companies are at the forefront, providing cutting-edge platforms for spatially resolved genomic and transcriptomic profiling.

Moreover, the market has been further shaped by strategic collaborations, mergers, and R&D investments, which enable companies to expand their global presence and introduce innovative solutions. With the increasing focus on understanding tissue architecture and disease mechanisms, the competitive landscape of the spatial genomics and transcriptomics market is dynamic, with innovation and customer-centric approaches driving differentiation and growth.

Market Segmentation for Spatial Genomics and Transcriptomics Market:

Segmentation 1: by Product Type

  • Kits and Assays
    • Sample Preparation Kits
    • Sample Enrichment Kits
  • Instrument
    • Slide Scanner
    • Microscopy
    • Mass Cytometry
  • Software
  • Services

Kits and Assays Segment to Dominate the Spatial Genomics and Transcriptomics Market (by Product Type)

Based on product type, the global spatial genomics and transcriptomics market was led by the kits and assays segment, which accounted for the largest share in 2023 and is expected to reach $1,116.2 million by 2034, registering a CAGR of 12.27% during the forecast period 2024-2034. This dominance can be attributed to their essential role in spatial analysis workflows, providing critical reagents and tools for sample preparation, staining, and detection. With applications spanning single-cell analysis, tissue profiling, and drug discovery, these products have become indispensable across research areas such as oncology, immunology, and neuroscience. Additionally, the services segment has gained traction, as many institutions and pharmaceutical companies increasingly rely on outsourcing services for customized analysis, data interpretation, and biomarker discovery. This combination of robust product offerings and expanding service capabilities is expected to propel the overall growth of the spatial genomics and transcriptomics market in the coming years.

Segmentation 2: by Sample Type

  • Fresh Frozen Tissues
  • Fixed Frozen Tissues
  • Formalin Fixed Paraffin Embedded (FFPE) Tissues
  • Cultured Cells

Fresh Frozen Tissues Segment to Dominate the Spatial Genomics and Transcriptomics Market (by Sample Type)

Based on sample type, the global spatial genomics and transcriptomics market was led by the fresh frozen tissues segment, which accounted for the largest share in 2023 and is expected to reach $1,131.8 million by 2034, registering a CAGR of 12.40% during the forecast period 2024-2034. Fresh frozen tissues are biological tissues that are frozen immediately after collection to preserve their molecular integrity. The segmental growth is primarily driven by the need to preserve tissue with intact morphology, proteins, DNA, and RNA for clinical research and diagnostic applications. Fresh frozen tissues maintain structural integrity and provide optimal permeabilization conditions, which are critical for research experiments. Leading companies such as 10x Genomics and Akoya Biosciences, Inc. offer advanced imaging technologies and solutions tailored for fresh frozen tissue types, further accelerating market expansion.

Segmentation 3: by Workflow

  • Spatial Imaging
    • Laser Capture Microdissection (LCM)
    • Immunohistochemistry (IHC)
    • Fluorescent In-Situ Hybridization (FISH)
    • Microscopy
    • Barcodes
    • Other
  • Spatial Sequencing
    • Next-Generation Sequencing (NGS)
    • In-Vivo Transcription
    • Fluorescent In-Situ Sequencing (FISSEQ)
    • Microtomy Sequencing
    • Other
  • Spatial Analysis
    • Data Visualization Tools
    • Data Analysis Tools

Spatial Imaging Segment to Dominate the Spatial Genomics and Transcriptomics Market (by Workflow)

Based on workflow, spatial imaging accounted for the largest share in 2023 and is expected to reach $1,095.7 million by 2034, registering a CAGR of 12.29% during the forecast period 2024-2034. Spatial imaging enables the exploration of the spatial organization of genetic material (DNA) and gene [removed]RNA) within their native tissue environment. The segment has experienced significant growth, driven by innovations in imaging technologies, mass cytometry, and mass spectrometry. Additionally, advancements in artificial intelligence (AI) and machine learning (ML) have further improved the accuracy and efficiency of image reconstruction, making real-time spatial imaging increasingly viable. By harnessing large datasets and adaptive learning algorithms, AI and ML address existing limitations, enhancing image processing and interpretation with greater precision and speed.

Segmentation 4: by Application

  • Diagnostics
    • Cancer Diagnostics
    • Neurology Diagnostics
    • Immunology Diagnostics
    • Other Diagnostics
  • Translation Research
  • Drug Discovery and Development
  • Single Cell Analysis
  • Cell Biology
  • Other

Drug Discovery and Development Segment to Dominate the Spatial Genomics and Transcriptomics Market (by Application)

Based on application, the drug discovery and development segment accounted for the largest share in 2023 and is expected to reach $688.4 million by 2034, registering a CAGR of 12.47% during the forecast period 2024-2034. The segment is majorly driven by the adoption of spatial technologies in identifying novel drug targets, understanding disease pathways, and optimizing preclinical studies through spatial insights into tissue microenvironments. Further, the growth of the market can be attributed to the high throughput techniques required for the discovery of therapeutic targets for drug development. Moreover, the advent of spatial biology, including gene expression microarray and high-throughput RNA-sequencing in clinical and drug research, has also furthered the market's growth.

Segmentation 5: by End User

  • Academic Institutes and Research Institutes
  • Biopharmaceutical and Biotechnology Companies
  • Contract Research Organization
  • Others

Academic Institutes and Research Institutes Segment to Dominate the Spatial Genomics and Transcriptomics Market (by End User)

Based on end user, academic institutes and research institutes accounted for the largest share in 2023 and are expected to reach $925.4 million by 2034, registering a CAGR of 12.47% during the forecast period 2024-2034. Academic and research institutions are among the primary end users of the spatial genomics and transcriptomics market. Research organizations constitute integral facilities for companies as well as independent academic research facilities. In the research laboratories, potential biomarkers are identified, and drugs are developed while acquiring targets through spatial analysis. In addition to this, research organizations are also responsible for exploring new opportunities for advancing gene expression analysis and capabilities.

Segmentation :6 by Region

  • North America
    • U.S.
    • Canada
  • Europe
    • Germany
    • U.K.
    • France
    • Italy
    • Spain
    • Rest-of-Europe
  • Asia-Pacific
    • China
    • Japan
    • India
    • Australia
    • Singapore
    • Rest-of-Asia-Pacific
  • Latin America
    • Brazil
    • Mexico
    • Rest-of-Latin America
  • Middle East and Africa

In the spatial genomics and transcriptomics market in 2023, the North America region dominated the global market, and it is expected to hold its dominance throughout the forecast period 2024-2034. This can be attributed to several key factors, including various technological innovations, drug discovery, and increasing research activities. In North America, several established spatial biology companies are focusing on expanding their portfolio in spatial genomics and transcriptomics instruments and kits. They are collaborating with service providers and pharmaceutical giants to co-market sequencing solutions with their complementary precision medicine solutions. Moreover, the availability of investors and venture capitalists capable of investing in the development of precision drugs and providing funds to start-ups in spatial biology has been furthering the market's growth.

Recent Developments in the Spatial Genomics and Transcriptomics Market

  • In July 2024, Illumina, Inc. announced the acquisition of Fluent BioSciences, a developer of innovative single-cell analysis technology. Fluent BioSciences has developed a unique single-cell analysis technology that eliminates the need for complex and expensive instrumentation and microfluidic consumables. This acquisition aligns with Illumina's broader strategy to advance its multiomics capabilities, particularly in single-cell research.
  • In May 2024, 10x Genomics launched a 5,000-plex gene panel for its Xenium platform, enabling researchers to analyze thousands of genes simultaneously in situ. The expanded gene panel offers unprecedented depth and detail, accelerating discoveries in tissue biology and disease mechanisms.
  • In January 2024, Akoya Biosciences, Inc. and Thermo Fisher Scientific announced a license and distribution agreement to deliver a spatial multiomics workflow. This collaboration combines Thermo Fisher's ViewRNA technology with Akoya's spatial biology solutions, enabling rapid, whole-slide imaging of RNA and protein biomarkers.

Demand - Drivers, Challenges, and Opportunities

Market Drivers:

Increasing Use of Spatial Omics for Drug Discovery and Development: The field of drug discovery and development is undergoing a transformative shift with the growing integration of spatial omics technologies, which are enabling a deeper and more accurate understanding of disease biology, therapeutic targets, and biomarkers of disease and therapeutic response. Traditional drug development heavily relied on bulk tissue samples, which often provided limited insights due to their inability to capture the heterogeneous nature of disease pathology. With the advent of spatial omics, including techniques such as digital spatial profiling (DSP), research scientists can now perform high-resolution, in situ analysis of RNA, DNA, and protein expression, offering unprecedented spatial context to the molecular landscape of disease tissues.

Market Challenges:

Lack of Skilled Professionals: A significant restraint in adopting and expanding spatial genomics and transcriptomics technologies is the lack of a skilled workforce. Clinical genomics laboratories, critical for implementing these advanced techniques, are already facing acute staff shortages, particularly in the U.S. As per an article titled ' Exploring current challenges in the technologist workforce of clinical genomics laboratories,' published in 2023, while medical technologists play a vital role in laboratory operations, the specialized nature of spatial genomics and transcriptomics demands expertise in both molecular biology and bioinformatics. This dual proficiency is not commonly available, further exacerbating workforce challenges.

Market Opportunities:

Integration of Artificial Intelligence in Spatial Genomics and Transcriptomics: The spatial genomics and transcriptomics market presents a significant opportunity driven by advancements in computational tools designed to enhance and impute spatial gene expression. These tools, leveraging cutting-edge artificial intelligence (AI) and deep learning technologies, are transforming data resolution and accuracy, addressing critical technical challenges in spatial transcriptomics (ST) analysis.

How can this report add value to an organization?

Product/Innovation Strategy: The global spatial genomics and transcriptomics market has been extensively segmented based on various categories, such as product type, sample type, workflow, application, end user, and region.

Growth/Marketing Strategy: Mergers, acquisitions, and product launches accounted for the maximum number of key developments.

Competitive Strategy: The global spatial genomics and transcriptomics market has numerous established players with product portfolios. Key players in the global spatial genomics and transcriptomics market analyzed and profiled in the study involve established players offering products for spatial genomics and transcriptomics.

Methodology

Key Considerations and Assumptions in Market Engineering and Validation

  • The base year considered for the calculation of the market size is 2023. A historical year analysis has been done for the period FY2020-FY2022. The market size has been estimated for FY2023 and projected for the period FY2024-FY2034.
  • The scope of this report has been carefully derived based on interactions with experts in different companies across the world. This report provides a market study of upstream and downstream products of the spatial genomics and transcriptomics market.
  • The market size was estimated and validated using both bottom-up and top-down analyses. The market size for each product type and end user was estimated for the bottom-up approach. These were further added to cumulate the global spatial genomics and transcriptomics market size.
  • The top-down analysis was conducted to determine the market contributions of various segments defined in the scope.
  • The market has been mapped based on the available spatial genomics and transcriptomics. This report has considered and profiled all the key companies with significant offerings in this field.
  • The base currency considered for the market analysis is US$. Currencies other than the US$ have been converted to the US$ for all statistical calculations, considering the average conversion rate for that particular year.

Primary Research:

The primary sources involve industry experts in spatial genomics and transcriptomics, including the market players offering products and services. Resources such as CEOs, vice presidents, marketing directors, and technology and innovation directors have been interviewed to obtain and verify both qualitative and quantitative aspects of this research study.

The key data points taken from the primary sources include:

  • validation and triangulation of all the numbers and graphs
  • validation of the report's segmentation and key qualitative findings
  • understanding the competitive landscape and business model
  • current and proposed production values of a product by market players
  • validation of the numbers of the different segments of the market in focus
  • percentage split of individual markets for regional analysis

Secondary Research

Open Sources

  • Certified publications, articles from recognized authors, white papers, directories, and major databases, among others
  • Annual reports, SEC filings, and investor presentations of the leading market players
  • Company websites and detailed study of their product portfolio
  • Gold standard magazines, journals, white papers, press releases, and news articles
  • Paid databases

The key data points taken from the secondary sources include:

  • segmentations and percentage shares
  • data for market value
  • key industry trends of the top players of the market
  • qualitative insights into various aspects of the market, key trends, and emerging areas of innovation
  • quantitative data for mathematical and statistical calculations

Key Market Players and Competition Synopsis

The companies profiled have been selected based on inputs gathered from primary experts, who have analyzed company coverage, product portfolio, and market penetration.

Some prominent names established in this market are:

  • 10x Genomics.
  • Bruker Corporation
  • Akoya Biosciences, Inc
  • Bio-Techne.

Table of Contents

Executive Summary

Scope and Definition

1 Global Spatial Genomics and Transcriptomics Market: Overview

  • 1.1 Market Overview
  • 1.2 Regulatory Framework
    • 1.2.1 U.S.
      • 1.2.1.1 Regulatory Requirements for Products Intended as Medical Devices
      • 1.2.1.2 Regulatory Requirements for Research Use Only (RUO) Products
    • 1.2.2 European Union (EU)
      • 1.2.2.1 Regulatory Requirements for Products Intended as Medical Devices
        • 1.2.2.1.1 EU Medical Device Regulation
        • 1.2.2.1.2 EU In Vitro Diagnostic Regulation
      • 1.2.2.2 Regulatory Requirements for Sequencing Labs in the EU
    • 1.2.3 Japan
      • 1.2.3.1 Regulatory Requirements for Products Intended as Medical Devices
      • 1.2.3.2 Regulatory Requirements in Japan
    • 1.2.4 China
      • 1.2.4.1 Regulatory Requirements for Products Intended as Medical Devices
  • 1.3 Patent Analysis
    • 1.3.1 Patent Filing Trend (by Country)
    • 1.3.2 Patent Filing Trend (by Year)
    • 1.3.3 Global Spatial Genomics and Transcriptomics Market, Supply Chain Analysis
    • 1.3.4 Global Spatial Genomics and Transcriptomics Market, Value Chain Analysis
  • 1.4 Market Dynamics Overview
    • 1.4.1 Market Drivers
      • 1.4.1.1 Increasing Use of Spatial Omics for Drug Discovery and Development
      • 1.4.1.2 Technological Advancements in Sequencing
      • 1.4.1.3 Increasing Research Funding in Spatial Transcriptomics
    • 1.4.2 Market Restraints
      • 1.4.2.1 High Capital Requirement Hampering the Global Reach
      • 1.4.2.2 Lack of Skilled Professionals
    • 1.4.3 Market Opportunities
      • 1.4.3.1 Integration of Artificial Intelligence in Spatial Genomics and Transcriptomics

2 Global Spatial Genomics and Transcriptomics Market (by Product), $Million, 2022-2034

  • 2.1 Kits and Assays
    • 2.1.1 Sample Preparation Kits
    • 2.1.2 Sample Enrichment Kits
  • 2.2 Instrument
    • 2.2.1 Slide Scanner
    • 2.2.2 Microscopy
    • 2.2.3 Mass Cytometry
  • 2.3 Software
  • 2.4 Services

3 Global Spatial Genomics and Transcriptomics Market (by Sample Type), $Million, 2022-2034

  • 3.1 Fresh Frozen Tissues
  • 3.2 Fixed Frozen Tissues
  • 3.3 Formalin Fixed Paraffin Embedded (FFPE) Tissues
  • 3.4 Cultured Cells

4 Global Spatial Genomics and Transcriptomics Market (by Workflow), $Million, 2022-2034

  • 4.1 Spatial Imaging
    • 4.1.1 Laser Capture Microdissection (LCM)
    • 4.1.2 Immunohistochemistry (IHC)
    • 4.1.3 Fluorescent In-Situ Hybridization (FISH) Cultured Cell
    • 4.1.4 Microscopy
    • 4.1.5 Barcodes
    • 4.1.6 Other
  • 4.2 Spatial Sequencing
    • 4.2.1 Next-Generation Sequencing (NGS)
    • 4.2.2 In-Vivo Transcription
    • 4.2.3 Fluorescent In-Situ Sequencing (FISSEQ)
    • 4.2.4 Microtomy Sequencing
    • 4.2.5 Others
  • 4.3 Spatial Analysis
    • 4.3.1 Data Visualization Tools
    • 4.3.2 Data Analysis Tools

5 Global Spatial Genomics and Transcriptomics Market (by Application), $Million, 2022-2034

  • 5.1 Diagnostics
    • 5.1.1 Cancer Diagnostics
    • 5.1.2 Neurology Diagnostics
    • 5.1.3 Immunology Diagnostics
    • 5.1.4 Other Diagnostics
  • 5.2 Drug Discovery and Development
  • 5.3 Translational Research
  • 5.4 Single Cell Analysis
  • 5.5 Cell Biology
  • 5.6 Other

6 Global Spatial Genomics and Transcriptomics Market (by End User), $Million, 2022-2034

  • 6.1 Academic Institutes and Research Institutes
  • 6.2 Biopharmaceutical and Biotechnology Companies
  • 6.3 Contract Research Organization
  • 6.4 Other End Users

7 Global Spatial Genomics and Transcriptomics Market (By Region), $Million, 2022-2034

  • 7.1 North America
    • 7.1.1 Regional Overview
    • 7.1.2 Driving Factors for Market Growth
    • 7.1.3 Factors Challenging the Market
      • 7.1.3.1 U.S.
      • 7.1.3.2 Canada
  • 7.2 Europe
    • 7.2.1 Regional Overview
    • 7.2.2 Driving Factors for Market Growth
    • 7.2.3 Factors Challenging the Market
      • 7.2.3.1 Germany
      • 7.2.3.2 U.K.
      • 7.2.3.3 France
      • 7.2.3.4 Italy
      • 7.2.3.5 Spain
      • 7.2.3.6 Rest-of-Europe
  • 7.3 Asia-Pacific
    • 7.3.1 Regional Overview
    • 7.3.2 Driving Factors for Market Growth
    • 7.3.3 Factors Challenging the Market
      • 7.3.3.1 China
      • 7.3.3.2 Japan
      • 7.3.3.3 India
      • 7.3.3.4 Australia
      • 7.3.3.5 Singapore
      • 7.3.3.6 Rest-of-Asia-Pacific
  • 7.4 Latin America
    • 7.4.1 Regional Overview
    • 7.4.2 Driving Factors for Market Growth
    • 7.4.3 Factors Challenging the Market
      • 7.4.3.1 Brazil
      • 7.4.3.2 Mexico
      • 7.4.3.3 Rest-of-Latin America
  • 7.5 Middle East and Africa
    • 7.5.1 Regional Overview
    • 7.5.2 Driving Factors for Market Growth
    • 7.5.3 Factors Challenging the Market

8 Competitive Insights and Company Profiles

  • 8.1 Key Strategies and Development
    • 8.1.1 Synergistic Activities
    • 8.1.2 Funding and Expansion
    • 8.1.3 Mergers and Acquisitions
    • 8.1.4 Funding Activities
    • 8.1.5 Service/Product Launches
  • 8.2 Company Profiles
    • 8.2.1 10x Genomics.
      • 8.2.1.1 Overview
      • 8.2.1.2 Top Products
      • 8.2.1.3 Top Competitors
      • 8.2.1.4 Target Customers/End Users
      • 8.2.1.5 Analyst View
    • 8.2.2 Akoya Biosciences, Inc.
      • 8.2.2.1 Overview
      • 8.2.2.2 Top Products
      • 8.2.2.3 Top Competitors
      • 8.2.2.4 Target Customers/End Users
      • 8.2.2.5 Analyst View
    • 8.2.3 Bruker Corporation
      • 8.2.3.1 Overview
      • 8.2.3.2 Top Products
      • 8.2.3.3 Top Competitors
      • 8.2.3.4 Target Customers/End Users
      • 8.2.3.5 Analyst View
    • 8.2.4 Bio-Techne.
      • 8.2.4.1 Overview
      • 8.2.4.2 Products Offered
      • 8.2.4.3 Top Competitors
      • 8.2.4.4 Target Customers/End Users
      • 8.2.4.5 Analyst View
    • 8.2.5 BioSpyder, Inc.
      • 8.2.5.1 Overview
      • 8.2.5.2 Top Products
      • 8.2.5.3 Top Competitors
      • 8.2.5.4 Target Customers/End Users
      • 8.2.5.5 Analyst View
    • 8.2.6 Flagship Biosciences, Inc.
      • 8.2.6.1 Overview
      • 8.2.6.2 Products Offered
      • 8.2.6.3 Top Competitors
      • 8.2.6.4 Target Customers/End Users
      • 8.2.6.5 Analyst View
    • 8.2.7 Illumina, Inc.
      • 8.2.7.1 Overview
      • 8.2.7.2 Top Products
      • 8.2.7.3 Top Competitors
      • 8.2.7.4 Target Customers/End Users
      • 8.2.7.5 Analyst View
    • 8.2.8 Miltenyi Biotec
      • 8.2.8.1 Overview
      • 8.2.8.2 Products Offered
      • 8.2.8.3 Top Competitors
      • 8.2.8.4 Target Customers/End Users
      • 8.2.8.5 Analyst View
    • 8.2.9 MGI Tech Co., Ltd.
      • 8.2.9.1 Overview
      • 8.2.9.2 Top Products
      • 8.2.9.3 Top Competitors
      • 8.2.9.4 Target Customers/End Users
      • 8.2.9.5 Analyst View
    • 8.2.10 RareCyte, Inc.
      • 8.2.10.1 Overview
      • 8.2.10.2 Products Offered
      • 8.2.10.3 Top Competitors
      • 8.2.10.4 Target Customers/End Users
      • 8.2.10.5 Analyst View
    • 8.2.11 Revvity, Inc.
      • 8.2.11.1 Overview
      • 8.2.11.2 Top Products and Services
      • 8.2.11.3 Top Competitors
      • 8.2.11.4 Analyst View
    • 8.2.12 S2 Genomics, Inc.
      • 8.2.12.1 Overview
      • 8.2.12.2 Top Products
      • 8.2.12.3 Top Competitors
      • 8.2.12.4 Target Customers/End Users
      • 8.2.12.5 Analyst View
    • 8.2.13 Standard BioTools
      • 8.2.13.1 Overview
      • 8.2.13.2 Product Offered
      • 8.2.13.3 Top Competitors
      • 8.2.13.4 Target Customers/End Users
      • 8.2.13.5 Analyst View
    • 8.2.14 TissueGnostics GmbH
      • 8.2.14.1 Overview
      • 8.2.14.2 Top Products
      • 8.2.14.3 Top Competitors
      • 8.2.14.4 Target Customers/End Users
      • 8.2.14.5 Analyst View
    • 8.2.15 Vizgen Inc.
      • 8.2.15.1 Overview
      • 8.2.15.2 Services Offered
      • 8.2.15.3 Top Competitors
      • 8.2.15.4 Target Customers/End Users
      • 8.2.15.5 Analyst View

9 Research Methodology

  • 9.1 Data Sources
    • 9.1.1 Primary Data Sources
    • 9.1.2 Secondary Data Sources
    • 9.1.3 Data Triangulation
  • 9.2 Market Estimation and Forecast

List of Figures

  • Figure 1: Global Spatial Genomics and Transcriptomics Market, $Million, 2024, 2028, and 2034
  • Figure 2: Global Spatial Genomics and Transcriptomics Market (by Region), $Million, 2023, 2028, and 2034
  • Figure 3: Global Spatial Genomics and Transcriptomics Market (by Product Type), $Million, 2023, 2028, and 2034
  • Figure 4: Global Spatial Genomics and Transcriptomics Market (by Workflow), $Million, 2023, 2028, and 2034
  • Figure 5: Global Spatial Genomics and Transcriptomics Market (by Application), $Million, 2023, 2028, and 2034
  • Figure 6: Number of Patents in Spatial Genomics and Transcriptomics Market (by Country), January 2021-December 2024
  • Figure 7: Number of Patents in Spatial Genomics and Transcriptomics Market (by Year), January 2021-December 2024
  • Figure 8: Supply Chain Analysis: Global Spatial Genomics and Transcriptomics Market
  • Figure 9: Global Spatial Genomics and Transcriptomics Market, Value Chain Analysis
  • Figure 10: Advances in Spatial Transcriptomics
  • Figure 11: North America Spatial Genomics and Transcriptomics Market, $Million, 2022-2034
  • Figure 12: U.S. Spatial Genomics and Transcriptomics Market, $Million, 2022-2034
  • Figure 13: Canada Spatial Genomics and Transcriptomics Market, $Million, 2022-2034
  • Figure 14: Europe Spatial Genomics and Transcriptomics Market, $Million, 2022-2034
  • Figure 15: Germany Spatial Genomics and Transcriptomics Market, $Million, 2022-2034
  • Figure 16: U.K. Spatial Genomics and Transcriptomics Market, $Million, 2022-2034
  • Figure 17: France Spatial Genomics and Transcriptomics Market, $Million, 2022-2034
  • Figure 18: Italy Spatial Genomics and Transcriptomics Market, $Million, 2022-2034
  • Figure 19: Spain Spatial Genomics and Transcriptomics Market, $Million, 2022-2034
  • Figure 20: Rest-of-Europe Spatial Genomics and Transcriptomics Market, $Million, 2022-2034
  • Figure 21: Asia Pacific Spatial Genomics and Transcriptomics Market, $Million, 2022-2034
  • Figure 22: China Spatial Genomics and Transcriptomics Market, $Million, 2022-2034
  • Figure 23: Japan Spatial Genomics and Transcriptomics Market, $Million, 2022-2034
  • Figure 24: India Spatial Genomics and Transcriptomics Market, $Million, 2022-2034
  • Figure 25: Australia Spatial Genomics and Transcriptomics Market, 2022-2034
  • Figure 26: Singapore Spatial Genomics and Transcriptomics Market, $Million, 2022-2034
  • Figure 27: Rest-of-Asia-Pacific Spatial Genomics and Transcriptomics Market, $Million, 2022-2034
  • Figure 28: Latin America Spatial Genomics and Transcriptomics Market, $Million, 2022-2034
  • Figure 29: Brazil Spatial Genomics and Transcriptomics Market, $Million, 2022-2034
  • Figure 30: Mexico Spatial Genomics and Transcriptomics Market, $Million, 2022-2034
  • Figure 31: Rest-of-Latin America Spatial Genomics and Transcriptomics Market, $Million, 2022-2034
  • Figure 32: Middle East and Africa Spatial Genomics and Transcriptomics Market, $Million, 2022-2034
  • Figure 33: Synergistic Activities, January 2020- December 2024
  • Figure 34: Funding and Expansion, January 2020-December 2024
  • Figure 35: Product Launches (by Company), January 2021-September 2024
  • Figure 36: Data Triangulation
  • Figure 37: Top-Down and Bottom-Up Approach
  • Figure 38: Assumptions and Limitations

List of Tables

  • Table 1: Market Snapshot
  • Table 2: Global Spatial Genomics and Transcriptomics Market Opportunities
  • Table 3: Impact Analysis of Market Navigating Factors, 2022-2034
  • Table 4: Recent Funding in Spatial Genomics and Transcriptomics Market
  • Table 5: Cost Associated with Spatial Genomics and Transcriptomics Instruments
  • Table 6: Global Spatial Genomics and Transcriptomics Market (by Product Type), $Million, 2022-2034
  • Table 7: Global Spatial Genomics and Transcriptomics Market (by Kits and Assays), $Million, 2022-2034
  • Table 8: Global Spatial Genomics and Transcriptomics Market (by Instruments), $Million, 2022-2034
  • Table 9: Global Spatial Genomics and Transcriptomics Market (by Sample Type), $Million, 2022-2034
  • Table 10: Global Spatial Genomics and Transcriptomics Market (by Workflow), $Million, 2022-2034
  • Table 11: Global Spatial Genomics and Transcriptomics Market (by Spatial Imaging), $Million, 2022-2034
  • Table 12: Global Spatial Genomics and Transcriptomics Market (by Spatial Sequencing), $Million, 2022-2034
  • Table 13: Global Spatial Genomics and Transcriptomics Market (by Spatial Analysis), $Million, 2022-2034
  • Table 14: Global Spatial Genomics and Transcriptomics Market (by Application), $Million, 2022-2034
  • Table 15: Global Spatial Genomics and Transcriptomics Market (by Diagnostic), $Million, 2022-2034
  • Table 16: Global Spatial Genomics and Transcriptomics Market (by End User), $Million, 2022-2034
  • Table 17: Mergers and Acquisitions (by Company), January 2020-December 2024
  • Table 18: Funding Activities Share (by Company), January 2020-December 2024